Last 48 quarters of trend data · Healthcare · Life Science Tools
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.36 | — | — | — | — | — | — | — | 59.42 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.35 | 4.55 | 3.34 | 2.71 | 3.16 | 2.50 | 2.34 | 2.36 | 3.58 | 2.90 | 2.59 | 6.51 | 11.23 | 9.56 | 17.48 | 18.01 | 16.91 | 10.11 | 6.99 | 15.24 | 31.35 |
| — | +81.5% | +42.9% | +15.2% | -11.7% | -13.7% | -9.7% | -63.8% | -68.1% | -69.6% | -85.2% | -63.8% | -33.6% | -5.5% | +149.9% | +18.2% | -46.0% | -74.3% | -87.7% | -72.7% | -35.6% | |
| P/B Ratio | 126.74 | 16.20 | — | 170.61 | 105.55 | 10.67 | 6.05 | 3.82 | 1.11 | 1.02 | 0.76 | 1.56 | 3.74 | 2.79 | 5.18 | 4.05 | 3.29 | 2.09 | 1.46 | 2.75 | 5.71 |
| — | +51.8% | — | +4363.2% | +9420.8% | +942.1% | +699.2% | +145.4% | -70.3% | -63.3% | -85.4% | -61.5% | +13.7% | +33.7% | +256.0% | +47.1% | -42.4% | -68.1% | -94.6% | -88.1% | -63.8% | |
| P/FCF | — | 20.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | 54.13 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.7% | 33.2% | 32.4% | 34.5% | 37.5% | 39.2% | 36.9% | -3.7% | 25.6% | 25.0% | 16.5% | 29.1% | 16.4% | 32.1% | 32.7% | 25.1% | 18.8% | 41.9% | 45.7% | 42.7% | 46.5% |
| — | -15.3% | -12.3% | +1036.0% | +46.3% | +56.6% | +124.0% | -112.7% | +56.3% | -22.1% | -49.5% | +15.9% | -12.7% | -23.3% | -28.4% | -41.2% | -59.6% | -4.8% | +1.6% | -4.7% | +10.8% | |
| Operating Margin | -348.5% | -91.2% | -114.4% | -102.0% | -92.3% | -101.0% | -112.8% | -1154.5% | -390.1% | -160.3% | -488.3% | -209.6% | -150.0% | -148.1% | -153.8% | -234.6% | -318.4% | -230.9% | -191.6% | -233.7% | -179.6% |
| — | +9.7% | -1.4% | +91.2% | +76.3% | +37.0% | +76.9% | -450.7% | -160.1% | -8.2% | -217.4% | +10.6% | +52.9% | +35.9% | +19.7% | -0.4% | -77.3% | -8.2% | -56.1% | -101.0% | -103.2% | |
| Net Margin | -341.5% | -93.3% | -114.7% | -22.3% | -90.4% | -98.9% | -105.4% | -1146.8% | 6.0% | -151.9% | -481.3% | -201.4% | -140.5% | -120.1% | -146.8% | -226.3% | -308.5% | -238.2% | -201.3% | -245.7% | -192.5% |
| — | +5.6% | -8.8% | +98.1% | -1595.9% | +34.9% | +78.1% | -469.3% | +104.3% | -26.5% | -227.9% | +11.0% | +54.4% | +49.6% | +27.1% | +7.9% | -60.3% | -602.4% | -50.3% | +18.5% | -169.7% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -213.5% | -613.8% | — | -214.5% | -194.8% | -77.9% | -54.8% | -142.4% | 0.5% | -12.8% | -30.4% | -11.6% | -11.2% | -9.5% | -10.5% | -14.0% | -14.2% | -11.8% | -10.1% | -10.7% | -8.5% |
| — | -688.1% | — | -50.6% | -39534.4% | -506.6% | -80.4% | -1130.2% | +104.4% | -35.0% | -190.0% | +17.4% | +21.1% | +19.1% | -3.9% | -31.3% | -67.0% | -490.8% | +33.8% | +62.4% | -126.4% | |
| ROA | -53.4% | -5.1% | -5.8% | -1.1% | -5.1% | -4.7% | -5.0% | -40.2% | 0.2% | -4.1% | -10.9% | -4.6% | -4.5% | -3.6% | -3.7% | -4.8% | -4.7% | -4.2% | -3.7% | -4.1% | -3.4% |
| — | -10.1% | -17.3% | +97.4% | -3008.5% | -13.7% | +54.4% | -777.6% | +103.9% | -14.9% | -192.3% | +4.7% | +4.4% | +14.3% | +0.4% | -16.3% | -37.2% | -513.0% | -14.1% | +60.6% | -116.4% | |
| ROIC | -45.8% | -5.0% | -5.3% | -4.2% | -4.5% | -4.2% | -4.7% | -34.7% | -9.5% | -3.7% | -9.3% | -4.1% | -4.7% | -4.6% | -4.1% | -5.5% | -5.3% | -4.3% | -4.0% | -4.6% | -3.7% |
| — | -20.2% | -13.4% | +87.9% | +52.9% | -14.0% | +50.0% | -740.5% | -100.0% | +20.2% | -126.0% | +25.6% | +10.8% | -6.8% | -4.7% | -21.2% | -45.5% | +18.7% | +28.5% | +47.5% | +59.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 142.07 | 14.12 | — | 297.29 | 141.98 | 19.48 | 11.37 | 7.63 | 1.33 | 2.03 | 1.88 | 1.44 | 1.33 | 1.22 | 1.46 | 1.37 | 1.68 | 1.51 | 1.39 | 1.30 | 1.21 |
| — | -27.5% | — | +3796.8% | +10596.6% | +858.7% | +505.7% | +431.6% | -0.3% | +65.9% | +28.5% | +5.1% | -21.0% | -19.1% | +4.8% | +5.3% | +39.5% | +33.5% | -61.5% | -61.2% | +864.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.89 | 9.47 | 4.92 | 5.65 | 6.89 | 6.24 | 6.92 | 6.68 | 7.48 | 9.74 | 8.01 | 9.28 | 7.81 | 4.80 | 3.45 | 3.69 | 3.24 | 11.19 | 11.50 | 16.87 | 15.36 |
| — | +51.9% | -28.9% | -15.4% | -7.8% | -35.9% | -13.7% | -28.0% | -4.3% | +103.0% | +132.5% | +151.3% | +141.3% | -57.2% | -70.0% | -78.1% | -78.9% | -44.9% | -56.1% | -52.4% | +66.3% | |
| Quick Ratio | 5.99 | 7.62 | 4.03 | 4.87 | 5.99 | 5.40 | 6.02 | 5.87 | 6.59 | 8.64 | 7.14 | 8.36 | 7.21 | 4.43 | 3.20 | 3.46 | 3.04 | 10.66 | 11.07 | 16.38 | 15.01 |
| — | +41.2% | -33.0% | -17.0% | -9.2% | -37.6% | -15.7% | -29.8% | -8.6% | +95.3% | +123.2% | +141.6% | +136.9% | -58.5% | -71.1% | -78.9% | -79.7% | -46.7% | -57.1% | -53.1% | +69.3% | |
| Interest Coverage | -77.52 | -17.27 | -20.18 | -5.65 | -22.09 | -20.63 | -23.11 | -244.47 | 1.97 | -16.16 | -47.93 | -20.87 | -22.17 | -20.62 | -18.65 | -23.25 | -22.00 | -20.01 | -18.44 | -21.09 | -18.59 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PACB stock.
Pacific Biosciences of California, Inc.'s current P/E is -5.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pacific Biosciences of California, Inc.'s current operating margin is -348.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pacific Biosciences of California, Inc.'s business trajectory between earnings reports.